Back to search results

HEME Home Transfusion Program for Blood Cancers in Hospice

This study is looking at a new program called HEME-Hospice. This program combines home blood transfusions with regular hospice care for people with blood cancers like leukemia or myeloma. Many people with blood cancers need transfusions to help with symptoms like tiredness and bleeding, but most hospices don't offer them at home. This study wants to see if HEME-Hospice helps more people enroll in hospice, improves their quality of life and mood, and changes how they use healthcare at the end of life. You might be able to join if you are 18 or older, have a blood cancer that has come back or is hard to treat, and have received care at DFCI. The study is currently unclear on its recruitment status.

Study design
This study is an interventional trial with a planned enrollment of 700 participants. It is a cluster randomized trial, meaning groups of doctors will be randomly assigned to offer either HEME-Hospice or usual care.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The study will measure hospice enrollment and length of hospice enrollment at 6 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06487247

HEME Home Transfusion Program

Recruiting
NAAges 18+InterventionalSupportive care
Dana-Farber Cancer Institute
~700 participants
Updated 2025-09-17 on ClinicalTrials.gov
What's tested:HEME-Hospice Program

At a glance

Recruiting sites
2 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Hospice Enrollment Rate
Measured over 6 months
+1 more outcome measured

Conditions

Leukemia
Myeloma
Myelodysplastic Syndromes
Hematologic Malignancy
Hematologic Diseases
Lymphoma

Explore related trials

Hematopoietic and Lymphoid Cell DisorderLeukemiaLymphomaMalignant neoplasm of lymphoid, hematopoietic and/or related tissueMultiple MyelomaMyelodysplastic Syndrome

Where it's being run

2 sites across 1 states
Massachusetts2

Study leadership

  • Oreofe Odejide, MD, MPH · PRINCIPAL_INVESTIGATOR · Dana-Farber Cancer Institute

Who to contact

Oreofe Odejide, MD, MPH
[email protected]
617-632-6864
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Diagnosis of a relapsed/refractory hematologic malignancy
Age ≥ 18 years
Receipt of primary oncologic care at DFCI (at least 2 outpatient visits in 12 months prior to enrollment)
Has received at least one red blood cell (RBC) or platelet transfusion since blood cancer diagnosis in the clinic or hospital setting without a severe transfusion reaction
Patient resides within catchment served by Care Dimensions Hospice
Physician-estimated prognosis of six months or less
Identified informal caregiver of enrolled patient with hematologic malignancy
Age ≥ 18 years

Exclusion

Age \< 18 years
Already enrolled in hospice
Resides in nursing home or assisted living facility
History of previous serious adverse transfusion reaction
Age \< 18 years

What this trial measures

  • Hospice Enrollment Rate6 months

    Establish that hospice enrollment rate is higher with access to HEME-Hospice versus usual care.

  • Length of Hospice Enrollment6 months

    Number of days from hospice enrollment to date of death or hospice disenrollment